Bayer gains exclusive licence for heart drug in Japan

Agreement provides for €140 million in upfront and additional payments to Cytokinetics and up to €490 million in milestone payments, with tiered royalties on future sales | “Important regional deal” comes as Bayer’s new partner eyes US and European markets.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bayer gains exclusive licence for heart drug in Japan

Editor's picks

Editor's picks

More features